Global Companion Animal Cardiac Drugs Market 2025 – 2034

As per the Companion Animal Cardiac Drugs Market analysis conducted by the CMI team, the companion animal cardiac drugs market is expected to record a CAGR of 9.28% from 2025 to 2034. In 2025, the market size was USD 2.38 Billion. By 2034, the valuation is anticipated to reach USD 5.28 Billion.

Overview

Rise in the number of pets battling heart diseases such as hypertension, congestive heart failure, dilated cardiomyopathy, and arrhythmia is amongst the major factors driving the usage of cardiac drugs. Also, growing emphasis on early diagnoses followed by suitable therapies improves longevity and quality of life. With pet owners getting visibly attached to the pets, the companion animal cardiac drugs market is expected to grow on a staggering note.

Rise in penetration of pet insurance is playing a vital role in driving growth of the market. Providers such as Trusted Insurance Services Ltd. And Frank do offer varied insurance plans covering illnesses such as cancer, heart disease, diabetes, arthritis, and the other chronic conditions. The coverage does ease monetary strain on the pet owners, thereby facilitating advanced treatments.

Key Trends & Drivers

• Growing Prevalence of Cardiac Ailments

The rise in prevalence of cardiac ailments in the domestic animals – especially in elderly cats and dogs – are amongst the critical forces driving the companion animal cardiac drug market, as they need long-term and more comprehensible treatment. Yearly check-ups at the vets are gaining popularity in detecting mitral valve, congested heart failure, and dilated cardiomyopathy, as they are prescribed with the long-term regimes now.

The American Veterinary Medical Association (AVMA) mentions that 15% of cats and 10% of dogs are likely to contract heart ailments. This prevalence of cardiac ailments does highlight the requirement for continuous demand for the cardiac-targeted drugs like beta-blockers, ACE inhibitors, and diuretics. Plus, pet owners are ready to invest on cardiac treatment in order to prolong the lifespan of their pets.

• Rise in Pet Humanization

The owners, through rising humanization of pets, do look upon them as a part of the family, which does encourage their increased interest in cardiac health and desire to deploy specified heart treatments. This positive change is reflected in the active approach toward veterinary treatment, wherein emotional connection does make owners emphasize diagnostic examinations and long-term drug prescriptions analogous to practices in human healthcare.

The American Pet Products Association (APPA) states that over 8 out of 10 Americans treat pets as a part of their families. This emotional bondage of a higher level does inspire investments into beta-blockers or ACE inhibitors, thereby prompting compliance with the prescribed practices. Furthermore, uptake of the pet insurance is on the rise. Ultimately, the trend of humanization is turning veterinary cardiac care into a proactive step rather than a reactive one.

What’s trending in the Companion Animal Cardiac Drugs Market?

Companion animal cardiac drugs have been prescribed for treating conditions such as hypertension, heart failure, arrhythmias, and various other heart diseases that are typical of genetically predisposed or aging animals. The medications do operate by improving the heart’s functionality, enhancing circulation, and controlling blood pressure for the betterment of lives and quality of pets.

Veterinarians are into the prescription of more specialized cardiac drugs for better treating the patients with a comprehensible method that could also need continuous monitoring and alteration in diet. With the veterinary industry advancing with respect to diagnostic potential and medical care, earlier detection on the part of cardiac problems is turning out to be the need of the hour.

Key Threats

Higher price of cardiac medication is amongst the restraints to the companion animal cardiac drug market, as numerous pet owners find it unaffordable. Also, the special drugs, such as beta-blockers, ACE inhibitors, and inotropes, may result in notable recurrent costs. They could also be prohibitive to the middle-income animal owners or the ones who own more than one animal, and some of them may also avoid or delay treatment.

Besides, in the areas having low pet insurance, owners are required to cover 100% of the monetary cost of the chronic cardiac treatment. The cost of drugs may also increase due to dependency on the imported or innovative formulations.

Opportunities

• Expansion of Online Veterinary Pharmacies

Online veterinary pharmacies are turning out to be leading opportunities for the expansion of the companion animal cardiac drug market, as cardiac drugs are just a few clicks away. With such platforms, owners of these pets can conveniently order the prescribed medications such as beta-blockers, ACE inhibitors, and diuretics without the need for traveling to physical pharmacies and clinics. The online drug stores do provide subscriptions as well as deliveries at homes, which do guarantee use of chronic heart care over the period of time.

Also, the internet is capable of offering educational resources as well as reminders regarding the way drugs could be used properly and improve quality pertaining to treatment adherence. This is handy, particularly to the owners living in poorly served or remote areas where they do have limited access to the special veterinary services. The expansion of the market is supported by the rise in acceptability of e-Commerce in animal healthcare. The online channels are making provisions for scalable opportunities for accessing wider audiences and promoting awareness and using the companion animal cardiac drugs.

• Development of New Formulations such as Flavored and Chewable Liquids

Introducing new formulations such as flavoured and chewable liquids does offer a visible potential in the companion animal cardiac drug market, as it emphasizes solving the majority of issues in giving the medicines to pets. Certain animals do find it tough to swallow the regular capsules or tablets, which could jeopardize outcomes of the cardiac health. Chewable and palatable liquid preparations improve compliance as they simplify administration of drugs and make administering them more enjoyable to pets and their owners.

Category Wise Insights

By Animal Type

• Dogs

The dogs segment holds more than 60% of the market share. This is due to the fact that dogs are amongst the most preferred companion animals, wherein they have surpassed cats as well as the other animals with regard to popularity. Also, their rising presence in the households corresponds to increased pet health expenditure. The growing number of families owning flowers has sizably boosted the demand for veterinary care, which includes specialized treatments like cardiac treatments.

For instance – around 87 million households in the U.S. own a pet, with dogs being a part of close to 65 million households. This dominance does highlight dogs’ central role in pet population, thereby driving the higher spending on healthcare and extending support to the growth of cardiac drug adoption and veterinary care services.

• Cats

The cats segment is expected to witness the quickest growth in the global companion animal cardiac drugs market, which is accelerated by growing incidences of heart-related disorders along with raised obesity in the cats. Studies by the Purina Institute state that nearly 63% of the pet cats are obese or overweight. Extra weight does place an additional strain on the cardiovascular system, which contributes to reduction in cardiac efficiency, hypertension, and higher risk of getting heart ailments.

Purina Institute also states that almost 15% of cats are adversely affected by cardiac conditions, with more than 60% of them contracting cardiomyopathies. This link between cardiovascular disorders and obesity does underscore the requirement for effective management strategies inclusive of cardiac drugs so as to better the health outcomes in felines in the long run.

• Horses

Rising population of horses worldwide is driving the growth of the equine therapeutics and healthcare market, thereby driving the need for companion animal cardiac drugs. Cardiac drugs are amongst the discrete segments of the market. Also, expansion of the equestrian activities and sports does create a greater number of opportunities for horses and, ultimately, an increased need for maintenance of their health.

By Product

• Pimobendan

The pimobendan segment holds over 40% of the market share. This is reasoned with pimobendan being the standard of care regarding management of congestive heart failure, especially in the dogs battling myxomatous mitral valve disease (MMVD) or dilated cardiomyopathy (DCM). Broadly recommended as veterinary guidelines, pimobendan does extend survival time as well as improve quality of life in the affected pets.

• Spironolactone and Benazepril Hydrochloride

Spironolactone and benazepril hydrochloride provide an effective, FDA-approved combination therapy for congestive heart failure (CHF) in dogs, especially those suffering from MMVD. This combination called Cardalia overpowers benazepril alone by blocking the renin-angiotensin-aldosterone system (RAAS) at the two key points, which do curtail cardiac remodeling and enhance quality of life. The dual-action therapy is amongst the core components of broadly recognized quadruple therapy for MMVD, which improve owner compliance.

• Furosemide

Furosemide is categorized as a loop diuretic, which translates into the fact that it does act on the dog’s kidney’s specific part – called loops of Henle. Furosemide does prevent water and sodium from getting reabsorbed so that they can be excreted in the form of urine. The dog, with aging, is likely to develop a condition called degenerative mitral valve disease (DMVD). It is known for causing heart failure in dogs. The American College of Veterinary Internal Medicine (ACVIM) does recommend drugs for spironolactone, enalapril, digoxin, pimobendan, and beta-blockers.

By Indication

• Congestive Heart Failure

The congestive heart failure segment holds over 35% of the market share. Himachal Journal of Agricultural Research published a study in June 2025, which does highlight vital demographic trends in the wake of congestive heart failure (CHF) amongst the dogs. It further mentions that this condition is more prevalent in the dogs weighing more than 15 Kg, thereby underscoring the role of cardiovascular strain in the development of diseases. Such insights focus on the need for early interventions and targeted monitoring in the higher-risk groups, especially bigger male dogs, for improving clinical outcomes and strengthening preventive veterinary care.

• Myocardial (Heart Muscle) Disease

Myocardial (heart muscle) diseases do increase occurrences of heart attacks in pets, which do drive demand for effective treatments, and also serve as valuable models for human as well as veterinary cardiac research and drug development. As the pets live longer, the likelihood of the development of chronic conditions such as heart disease does increase, thereby catalysing demand for the cardiac drugs. Traction in veterinary cardiology translates to a greater number of animals receiving specialized care for drugs to improve quality of life.

• Arrhythmias

Beta-blockers (such as atenolol) are used for controlling arrhythmias and stabilizing rhythmic movements of the heart, especially in cats suffering from hypertrophic cardiomyopathy. The ACE inhibitors (like benazepril and enalapril) are prescribed for reducing the workload on the heart along with slowing disease progression. Calcium channel blockers (like diltiazem) help in managing atrial arrhythmias by slowing the rate of heart attack.

By End-use

• Veterinary Hospitals & Clinics

The veterinary hospitals & clinics segment holds more than 55% of the market share. This is due to the fact that hospitals & clinics are the primary channels with respect to prescription and dispensation of medications, thereby ascertaining appropriate management and treatment of heart ailments in pets. The owners of pets do trust them for continuous monitoring, professional guidance, and adjustments regarding drug regimens, which do strengthen their role in the form of main distribution and care centers.

• Others

The ‘others’ segment is expected to witness the fastest CAGR during the forecast period. Academic as well as research institutes, apart from emergency and specialty animal care centers, do drive the companion animal cardiac drug market by enabling advanced clinical research, offering specialized care for the complex cardiac conditions, and developing new treatment protocols. These institutions not only act as referral hubs where the pets with rare or severe heart disorders receive the advanced diagnostics/therapies but also contribute toward clinical and educational trials that do expand adoption and availability of the new cardiac drugs.

By Distribution Channel

• Hospital/Clinic Pharmacy

The hospital/clinic pharmacy segment holds more than 60% of the market share. This is due to hospitals/clinic pharmacies acting as primary points of access for the prescribed medications, thereby ascertaining reliable and timely availability of the treatments for arrhythmias, heart failure, and congenital defects. Such pharmacies not only enable a controlled supply chain guaranteeing the authenticity and quality of drugs but also foster veterinarians to monitor the treatment compliance and adapt to therapies as required. With the growing prevalence of cardiac disorders in pets and the rising preference for veterinary care at the professional level, hospital/clinic pharmacies do strengthen the distribution network and foster accessibility, trust, and continuity of care.

• Retail

Retail, particularly through online veterinary pharmacies, does help in the expansion of the companion animal cardiac drug market by enhancing access, education, and convenience pertaining to pet owners. The online platforms allow for competitive pricing, subscription-based medication delivery, and an increase in adherence to chronic heart care, thereby reaching a wider customer base, especially in the remote areas. Retail platforms do enable subscription services and home delivery services for the chronic cardiac medications, thereby assuring continuous and consistent treatment adherence for the pets.

• e-Commerce

The e-Commerce segment is anticipated to witness the fastest growth rate during the forecast period. The online platforms and veterinary pharmacies simplify refilling prescriptions, comparing brands, and accessing specialized cardiac drugs that may not be available at the brick and mortar stores, thereby ascertaining treatment adherence for pets battling chronic heart ailments. Plus, the ongoing trend of telemedicine’s integration with e-Commerce platforms facilitates vets prescribing medications online and is encouraging growth of sales of companion animal cardiac drugs.

Historical Context

The companion animal cardiac drugs market is propelled by a combination of pharmaceutical, clinical, and awareness-driven initiatives. The collaborations between private clinics and veterinary schools in Alberta and Quebec have disseminated updated cardiac care protocols, thereby helping veterinarians in diagnosing and managing the heart conditions in a more effective manner. This has, in turn, increased the number of companion animals receiving treatment from time to time, thereby directly raising demand for the cardiac drugs.

Pharmaceutical firms such as Zoetics Canada and Boehringer Ingelheim are strengthening their provincial distribution networks, thereby ascertaining continuous availability of the advanced medications. Reliable access does encourage the vets to prescribe therapies with a higher level of confidence, thereby curtailing treatment gaps.

The U.S. FDA, in May 2024, approved various animal drugs, inclusive of therapies for canine heart failure. For instance, a torsemide oral solution called UpCard-CA1 did receive conditional approval to treat pulmonary edema in the dogs suffering from congestive heart failure caused by myxomatous mitral valve disease (MMVD). However, it is recommended to be used combined with established therapies like ACE inhibitors, spironolactone, and pimobendan.

How is AI shaping Companion Animal Cardiac Drugs Market?

Advancements at a rapid pace in AI technology facilitate the development of diagnostic tools capable of identifying diseases at their earlier stages, along with predicting outbreaks and offering customized treatment plans. Along these lines, Zoetis, in 2020, introduced Vetscan Imagyst, the very first type of technology with AI-enabled fecal analysis, AI blood smear testing, and digital cytology image transfer. AI-powered diagnostic and imaging systems improve the precision of veterinary diagnostics, thereby raising AI’s adoption in animal health. Smart tags, collars, and the other wearable devices abreast with sensors are capable of gathering crucial data like temperature, heart rate, location, and activity levels. As such, integrating AI with smart wearables not only enhances animal welfare but also optimizes the operational efficiencies for the pet owners and vets alike, thereby accelerating the market.

How are the U.S. Tariffs affecting Companion Animal Cardiac Drugs Market?

U.S. tariffs on the imported pharmaceuticals, inclusive of the ones for companion animals are likely to increase production costs, thereby resulting in higher retail prices for treatments and medications. This does raise concerns for veterinary clinics and pet owners, thereby potentially impacting animal welfare by limiting or delaying care. The market players are responding by looking for alternative suppliers and domestic sourcing for averting tariffs and subverting the supply chain disruptions. In the long run, the tariffs are also expected to affect innovation in the veterinary pharmaceutical sector, thereby slowing development of the newfangled life-saving treatments.

Report Scope

Regional Perspective

The companion animal cardiac drugs market is classified into North America, Europe, Asia Pacific, and LAMEA.

• North America

North America holds more than 35% of the market share owing to the increased rate of pet ownership in the U.S. along with the robust spending capacity of the pet owners regarding specialized treatments and advanced veterinary healthcare infrastructure. The American Pet Products Association (APPA) has reported that the U.S. pet care expenditure is rising on a significant note, with a major portion directed in the direction of veterinary medications and services, thereby reflecting rising awareness of the owners to shell out money for cardiac care for cats and dogs. It further states that pet expenditures did surpass USD 151.9 Bn in 2024 alone.

• Asia Pacific

The market for the Asia-Pacific is expected to witness the fastest CAGR during the forecast period. This is driven by a rise in awareness of pet health, especially in the urban regions. For example – in China, fast urbanization with attitudes shifting toward pet care has expedited demand for the specialized cardiac services. Facilities like the Shanghai Companion Animal Hospital do provide dedicated cardiology care.

Japan’s market is witnessing steadiness, basically fuelled by the rising population of pets and growing prevalence of age-related heart ailments in the companion animals. Aging pet population has specially driven the demand for inodilators, diuretics, and ACE inhibitors, which are necessary in order to manage chronic heart conditions such as congestive heart failure.

• Europe

Europe’s companion animal cardiac drug market is driven by rising ownership of pets with continual advancements in veterinary healthcare. In Spain and Italy, veterinary clinics are expanding blood pressure monitoring services for addressing requirements of senior pets. AniCura, in February 2024, did report that the senior pets represent a rising segment in Europe, with 33% of cats and 31% of dogs classified as elderly, which is expected to underscore demand for targeted cardiology services. As per the International Trade Administration, the year 2023 witnessed 45% of German households owning a pet, with 14% of them owning two or even more than two, totaling around 34.3 million pets across the country.

• LAMEA

Numerous universities in Brazil have launched specialized veterinary cardiology courses, thereby reflecting the rising demand for skilled personnel capable of addressing the complex cardiac ailments in pets. The major cities of LATAM such as Rosario and Buenos Aires, are witnessing notable growth in the advanced veterinary practices specializing in cardiology services. The UAE is witnessing an ongoing trend of pet adoption. In Saudi Arabia, the premium veterinary clinics are equipped for managing the complex conditions like arrhythmias and heart failure in companion animals. As of January 2025, the owner of a new pet in South Africa does spend an average of USD 2,700 on the vet fees in the very first year.

Key Developments

The companion animal cardiac drugs market is witnessing a notable organic and inorganic expansion. Some of the key developments include –

• In November 2024, VETMEDIN Solution was launched as the first U.S. FDA-approved oral solution. It is meant to manage canine congestive heart failure owing to myxomatous mitral valve disease (MMVD)/dilated cardiomyopathy (DCM).

• In February 2024, Boehringer Ingelheim entered into a partnership with Veeva Systems with the objective of enhancing its regulatory and clinical operations in animal health. The collaboration does aim to streamline clinical execution and accelerate the development of novel veterinary medicines, inclusive of targeting the cardiovascular diseases in animals.

• In August 2023, Boehringer Ingelheim India entered into a partnership with Vvaan Lifesciences Pvt. Ltd. to enhance the availability of veterinary cardiology treatments in rural areas and tier 2 cities.

Leading Players

The companion animal cardiac drugs market is highly niche. Some of the key players in the market include:

• Boehringer Ingelheim International GmbH
• Ceva
• Elanco
• Virbac
• Zoetis
• Dechra Pharmaceuticals PLC
• Bimeda Corporate
• Biogénesis Bagó
• Merck & Co. Inc.
• Vetoquinol SA
• Others

These firms apply numerous strategies to enter the market, including innovations and mergers and acquisitions, as well as collaboration. The companion animal cardiac drugs market is shaped by the presence of diversified players that compete based on product innovation, vertical integration, and cost efficiency.

The Companion Animal Cardiac Drugs Market is segmented as follows:

By Animal Type

• Dogs
• Cats
• Horses

By Product

• Pimobendan
• Spironolactone and Benazepril Hydrochloride
• Furosemide

By Indication

• Congestive Heart Failure
• Myocardial (Heart Muscle) Disease
• Arrhythmias

By End-use

• Veterinary Hospitals & Clinics
• Others

By Distribution Channel

• Hospital/Clinic Pharmacy
• Retail
• e-Commerce

Regional Coverage:

North America

• U.S.
• Canada
• Mexico
• Rest of North America

Europe

• Germany
• France
• U.K.
• Russia
• Italy
• Spain
• Netherlands
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• New Zealand
• Australia
• South Korea
• Taiwan
• Rest of Asia Pacific

The Middle East & Africa

• Saudi Arabia
• UAE
• Egypt
• Kuwait
• South Africa
• Rest of the Middle East & Africa

Latin America

• Brazil
• Argentina
• Rest of Latin America

[embedsocial_reviews id=”d4ae80cffae3d938f997111953699a733c8e6f99″]